NeurologyWire

Acorda Therapeutics to Acquire Civitas Therapeutics

From NeurologyWire

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinsons disease (PD). The acquisition also includes rights to Civitas proprietary ARCUSTM pulmon...

Login to read story

Thursday, October 16, 2014

Show last days of articles

MS radio will provide tips on pregnancy, exercise and lifest...

From NeurologyWire

MSology.com has launched MS Radio, an audio program. The first episode is a three-part roundtable discussion with four multiple sclerosis nurses from ...Full story

Email reminders to ClinicalTrials.gov researchers increase p...

From NeurologyWire

Sometimes, all it takes is an email.More researchers will post the results of their trials if they are sent an email reminder according to a study pub...Full story

DEA won't meddle with Cannabidiol production

From NeurologyWire

Insys Therapeutics says its has received DEA approval to manufacture synthetically its pharmaceutical grade Cannabidiol (CBD). The company has also be...Full story

Plan to Prevent Drug Shortages released

From NeurologyWire

ISPE, the International Society for Pharmaceutical Engineering, released its Drug Shortages Prevention Plan at its 2014 Annual Meeting in Las Vegas, N...Full story

Dopamine cell therapy for Parkinson's shows promise

From NeurologyWire

Just one shot of dopamine cells derived from stem cells could be enough to reverse many of the features of Parkinsons disease for decades and the bar...Full story

Wednesday, October 15, 2014

Rare Genetic Disease Protects Against Bipolar Disorder

From NeurologyWire

A team of scientists led by researchers at the UMass Medical School and the University of Miami Miller School of Medicine (UMMSM) have identified what...Full story

Study says effects of high-risk Parkinsons mutation are reve...

From NeurologyWire

Researchers from the University of Sheffield have found new evidence on how to target and reverse the effects caused by one of the most common genetic...Full story

Tuesday, October 14, 2014

Parkinson's award seeks applicants

From NeurologyWire

The application process for the George Cotzias Memorial Fellowship award is now open, according to the American Parkinson Disease Association. The goa...Full story

Scientists Link ALS Progression to Increased Protein Instabi...

From NeurologyWire

A new study suggests a cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease.Our work supports a common theme whereby loss o...Full story

Monday, October 13, 2014

Couches can be deadly for sleeping infants

From NeurologyWire

Couches are an extremely hazardous sleeping surface for infants, according to a new study published online Oct. 13 in Pediatrics.Deaths on sofas are a...Full story

Friday, October 10, 2014

Data mining yields Alzheimers discovery

From NeurologyWire

Researcher David Ashbrook and colleagues from the UK and USA used two of the worlds largest collections of scientific data to compare the genes in mic...Full story

FDA approves first drug-coated angioplasty balloon catheter

From NeurologyWire

The U.S. Food and Drug Administration has approved the Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB). T...Full story

Thursday, October 09, 2014

Gene therapy shows potential therapy route in ALS

From NeurologyWire

In work supported by The ALS Association, researchers have demonstrated the feasibility and potential therapeutic effectiveness of a form of gene ther...Full story

Scientists believe they can switch off autoimmune disorders

From NeurologyWire

Rather than the bodys immune system destroying its own tissue by mistake, researchers at the University of Bristol have discovered how cells convert f...Full story

Researchers find that Gaucher disease drug slows Parkinsons

From NeurologyWire

A new study from UCLA found that a drug being evaluated to treat an entirely different disorder helped slow the progression of Parkinsons disease in m...Full story